Clinical trial · Interventional
Study for Patients With Non Small Cell Lung Cancer (NSCLC)
Randomized Phase II Study to Determine the Efficacy of a Three Weekly vs. Weekly Therapy With Paclitaxel Plus Carboplatin vs. Paclitaxel Plus Vinorelbine for Patients With Non Small Cell Lung Cancer According to UICC Stage IIIB and IV
NCT00168883CI-TRIAL-00000493unknownPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a randomized study to assess the efficacy and safety of chemotherapy with platin compared to chemotherapy without platin.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Carcinoma, Non-Small-Cell Lung | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Carboplatin | Drug | Carboplatin | ALIAS |
| Paclitaxel | Drug | Paclitaxel | ALIAS |
| Vinorelbine | Drug | Vinorelbine | ALIAS |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (2)
- measure
- Determination of response rate (stable disease [SD] or better)
- measure
- Determination of safety of the combination and life quality
Secondary outcomes (3)
- measure
- Determination of remission rate
- measure
- Determination of time to progression
- measure
- Determination of 1-year survival rate
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Chemotherapy naive patients with histologically confirmed NSCLC stage III and IV Exclusion Criteria: * New York Heart Association (NYHA) III or IV * Brain metastases * Neurotoxicity Grade 2 or greater
References
Publications (0)
Data not yet available
No reference posted for this study.